One of the most richly funded biotechnology startups to launch in recent years now has more money to add to its pot. On Tuesday, Neumora Therapeutics revealed it’s raised $112 million from a battery of pharmaceutical and venture investors to advance its pipeline of brain disease drugs.
The Watertown, Mass.-based biotech emerged from stealth one year ago with $100 million from Amgen as well as $400 million from Arch Venture Partners and more than a dozen other firms.
